Phathom (PHAT) - Long-Term Debt to Capital Coefficient
Phathom Pharmaceuticals (PHAT) is scaling profits via its Voquezna patent, leveraging affordable contract manufacturing and insurance distribution channels, with the indicator standing at 0.00. This price chart illustrating value trends clearly confirms the business's financial momentum. The firm's strategy is based on the implementation of innovative PCAB drugs for esophagitis therapy, while operational efficiency is growing due to packaging automation and the digitalization of clinical documentation.
%20Long-Term%20Debt%20to%20Capital&width=1200&height=400&colorIndex=0&v=mvujvhid.si-7ayy9s0&start=20220704&end=20261030&filename=GURU_Markets_-_PHAT_-_Phathom-Pharmaceuticals_-_Long-Term-Debt-to-Capital "PHAT: Phathom Pharmaceuticals, Inc. Long-Term Debt to Capital 07/04/2022 - 10/30/2026 | 👁️GURU.Markets👁️")
Comprehensive metric breakdowns and analytics for Phathom Pharmaceuticals (PHAT)
For Phathom Pharmaceuticals (PHAT), which attracts top GI experts through stock option programs, the long-term debt-to-equity chart reflects the balance between debt financing and shareholder value. This ratio is calculated as the ratio of loans with a maturity of over one year to equity, allowing investors to assess the risk of excessive leverage and the likelihood of interest overpayments during periods of revenue stagnation.